CA2459077C - Diagnosis of ovarian carcinomas - Google Patents

Diagnosis of ovarian carcinomas Download PDF

Info

Publication number
CA2459077C
CA2459077C CA2459077A CA2459077A CA2459077C CA 2459077 C CA2459077 C CA 2459077C CA 2459077 A CA2459077 A CA 2459077A CA 2459077 A CA2459077 A CA 2459077A CA 2459077 C CA2459077 C CA 2459077C
Authority
CA
Canada
Prior art keywords
antibody
he4a
polypeptide
biological sample
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2459077A
Other languages
English (en)
French (fr)
Other versions
CA2459077A1 (en
Inventor
Michel Schummer
Ingegerd Hellstrom
Karl Erik Hellstrom
Jeffrey A. Ledbetter
Martha Hayden-Ledbetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Pacific Northwest Research Foundation
Original Assignee
University of Washington
Pacific Northwest Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Pacific Northwest Research Foundation filed Critical University of Washington
Publication of CA2459077A1 publication Critical patent/CA2459077A1/en
Application granted granted Critical
Publication of CA2459077C publication Critical patent/CA2459077C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2459077A 2001-08-29 2002-08-29 Diagnosis of ovarian carcinomas Expired - Lifetime CA2459077C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31653701P 2001-08-29 2001-08-29
US60/316,537 2001-08-29
PCT/EP2002/009653 WO2003021273A2 (en) 2001-08-29 2002-08-29 Diagnosis of carcinomas

Publications (2)

Publication Number Publication Date
CA2459077A1 CA2459077A1 (en) 2003-03-13
CA2459077C true CA2459077C (en) 2018-06-05

Family

ID=23229467

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2459077A Expired - Lifetime CA2459077C (en) 2001-08-29 2002-08-29 Diagnosis of ovarian carcinomas

Country Status (11)

Country Link
US (4) US7270960B2 (enExample)
EP (3) EP1421388A2 (enExample)
JP (5) JP2005501549A (enExample)
KR (1) KR20040062534A (enExample)
CN (1) CN1813188A (enExample)
BR (1) BR0212211A (enExample)
CA (1) CA2459077C (enExample)
ES (1) ES2628952T3 (enExample)
MX (1) MXPA04001963A (enExample)
RU (1) RU2004109149A (enExample)
WO (1) WO2003021273A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
MXPA06003402A (es) * 2003-10-07 2006-06-27 Millennium Pharm Inc Moleculas de acidos nucleicos y proteinas para la identificacion, evaluacion, prevencion y tratamiento de cancer de ovario.
WO2005072263A2 (en) * 2004-01-21 2005-08-11 Fujirebio America, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
EP2444805A3 (en) * 2004-01-21 2012-06-20 Fujirebio America, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
AU2005334481A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
EP1877795A4 (en) * 2005-05-02 2010-04-28 Brigham & Womens Hospital DIAGNOSTIC PROFILE MANUFACTURE OF SERUM ANTIBODIES
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
JP5164855B2 (ja) * 2006-01-04 2013-03-21 フジレビオ アメリカ、インク． 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
MX2008009592A (es) * 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
RU2328735C2 (ru) * 2006-08-16 2008-07-10 Федеральное государственное учреждение "Российский научно-исследовательский институт травматологии и ортопедии им. Р.Р. Вредена Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "РНИИТО им. Р.Р. Вредена Росмедтехнологий") Способ тестирования трупов-доноров на пригодность их тканей к трансплантации
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
BRPI0808655A2 (en) * 2007-03-09 2018-10-23 Tripath Imaging, Inc. he4 monoclonal antibodies and methods for their use.
US8455189B2 (en) * 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
WO2009099561A2 (en) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Urinary ca125 peptides as biomarkers of ovarian cancer
WO2009145815A2 (en) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
US8993347B2 (en) * 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
US20130095503A1 (en) * 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
JP6097688B2 (ja) * 2010-08-26 2017-03-15 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 抗ｈｅ４抗体を検出するための方法、ならびにｈｅ４発現細胞と関連する状態の診断および／または予後判定のための方法
RU2650778C2 (ru) * 2011-02-17 2018-04-17 Фуджиребио Диагностикс, Инк Композиции и способы применения для определения не4а
KR20140024860A (ko) * 2011-02-24 2014-03-03 버밀리언, 인코포레이티드 난소암에 대한 바이오마커 패널，진단 방법 및 시험 키트
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease
WO2012178102A2 (en) 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR102231139B1 (ko) 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CA2896951A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
US9903871B2 (en) * 2014-07-15 2018-02-27 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from nucleoredoxin X1 and uses thereof
WO2017032293A1 (zh) * 2015-08-21 2017-03-02 科济生物医药（上海）有限公司 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
RU2641094C1 (ru) * 2016-12-22 2018-01-15 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ ранней диагностики серозной карциномы яичника высокой степени злокачественности на основании изменения клеточного состава эпителия маточной трубы
WO2019060716A1 (en) 2017-09-25 2019-03-28 Freenome Holdings, Inc. SAMPLE EXTRACTION METHODS AND SYSTEMS
WO2020018381A1 (en) 2018-07-18 2020-01-23 The Regents Of The University Of California Kidney injury treatment
JP7539369B2 (ja) * 2019-04-02 2024-08-23 大塚製薬株式会社 病態情報生成方法、病態情報生成システム、ｈｅ４糖鎖分析キット及びｈｅ４
KR20220015367A (ko) 2019-05-31 2022-02-08 프리놈 홀딩스, 인크. 메틸화된 핵산의 고심도 시퀀싱 방법 및 시스템
AU2021245992A1 (en) 2020-03-31 2022-11-10 Freenome Holdings, Inc. Methods and systems for detecting colorectal cancer via nucleic acid methylation analysis
US20230243835A1 (en) * 2020-06-23 2023-08-03 Mitsui Chemicals, Inc. Adenocarcinoma detection method, and examination kit
CN116670510A (zh) 2020-10-05 2023-08-29 福瑞诺姆控股公司 用于结肠细胞增殖性病症的早期检测的标志物
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
EP4403634A1 (en) * 2021-09-16 2024-07-24 Qmine Co., Ltd. Antisense compound that regulates expression of wfdc2
US20240376473A1 (en) * 2021-09-16 2024-11-14 Qmine Co., Ltd. Antisense compound for modulating wfdc2 expression

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713352A (en) 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4612282A (en) 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
SE8300693L (sv) 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
US4579827A (en) 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
EP0198015B2 (en) 1984-10-02 1995-07-19 Biogen, Inc. Production of streptavidin-like polypeptides
US5272254A (en) 1984-10-02 1993-12-21 Biogen Inc. Production of streptavidin-like polypeptides
ZA858371B (en) 1984-11-02 1987-03-25 Oncogen Monoclonal antibodies for human non-small cell lung carcinomas
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
GB8723661D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US5093245A (en) 1988-01-26 1992-03-03 Applied Biosystems Labeling by simultaneous ligation and restriction
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5144019A (en) 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
US5272262A (en) 1989-06-21 1993-12-21 City Of Hope Method for the production of catalytic RNA in bacteria
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE4002981C2 (de) 1990-02-01 1998-03-12 Ihf Inst Fuer Hormon Und Fortp Humane, Epididymis-spezifische Polypeptide und deren Verwendung zur Therapie und Diagnose männlicher Infertilität
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
EP0644938A1 (en) 1992-05-29 1995-03-29 E.I. Du Pont De Nemours And Company PRODUCTION OF STREPTAVIDIN FROM $i(BACILLUS SUBTILIS)
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
WO1999023218A1 (fr) 1997-11-05 1999-05-14 Sumitomo Electric Industries, Ltd. PROTEINES DE FIXATION DE p16, GENE DE CES PROTEINES ET ANTICORPS CONTRE CES PROTEINES
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
CA2349444A1 (en) * 1998-11-03 2000-05-11 Mitokor Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2369433A1 (en) 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6770445B1 (en) * 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20030143234A1 (en) 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
AU7067000A (en) * 1999-08-24 2001-03-19 Texas Biotechnology Corporation A polynucleotide encoding a human junctional adhesion protein (jam-2)
WO2001016354A1 (en) 1999-09-02 2001-03-08 Gene Logic, Inc. Modulation of he4 in inflammatory and renal diseases
AU7701100A (en) * 1999-09-03 2001-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2001055301A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7279294B2 (en) * 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP1390497A2 (en) * 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP2315027A1 (en) 2002-08-16 2011-04-27 Decision Biomarkers Incorporated Substrates for isolating, reacting and microscopically analyzing materials
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
DE102004014645A1 (de) * 2004-03-25 2005-10-13 Mitsubishi Polyester Film Gmbh Transparente, elektrisch leitfähige, beschichtete Polyesterfolie, Verfahren zu ihrer Herstellung sowie ihre Verwendung
AU2005334481A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
WO2006089125A2 (en) 2005-02-16 2006-08-24 Dana-Farber Cancer Institute Methods of detecting ovarian cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007002535A2 (en) 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
JP5164855B2 (ja) 2006-01-04 2013-03-21 フジレビオ アメリカ、インク． 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
BRPI0808655A2 (en) * 2007-03-09 2018-10-23 Tripath Imaging, Inc. he4 monoclonal antibodies and methods for their use.
JP6097688B2 (ja) * 2010-08-26 2017-03-15 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 抗ｈｅ４抗体を検出するための方法、ならびにｈｅ４発現細胞と関連する状態の診断および／または予後判定のための方法
RU2650778C2 (ru) * 2011-02-17 2018-04-17 Фуджиребио Диагностикс, Инк Композиции и способы применения для определения не4а

Also Published As

Publication number Publication date
CA2459077A1 (en) 2003-03-13
EP2913673A1 (en) 2015-09-02
US20090104684A1 (en) 2009-04-23
JP2012161317A (ja) 2012-08-30
WO2003021273A3 (en) 2003-12-04
US20030108965A1 (en) 2003-06-12
WO2003021273A2 (en) 2003-03-13
JP2005501549A (ja) 2005-01-20
US9090712B2 (en) 2015-07-28
JP2016065870A (ja) 2016-04-28
JP2014081386A (ja) 2014-05-08
MXPA04001963A (es) 2005-02-17
HK1214346A1 (en) 2016-07-22
EP1421388A2 (en) 2004-05-26
JP5188443B2 (ja) 2013-04-24
KR20040062534A (ko) 2004-07-07
EP2913673B1 (en) 2017-05-31
JP5797136B2 (ja) 2015-10-21
RU2004109149A (ru) 2005-05-10
ES2628952T3 (es) 2017-08-04
JP2009195240A (ja) 2009-09-03
CN1813188A (zh) 2006-08-02
EP2322933A1 (en) 2011-05-18
BR0212211A (pt) 2004-08-17
US20100047818A1 (en) 2010-02-25
US7270960B2 (en) 2007-09-18
US20160033512A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
CA2459077C (en) Diagnosis of ovarian carcinomas
EP1169645B1 (en) Methods and compositions for diagnosing carcinomas
US6770445B1 (en) Methods and compositions for diagnosing carcinomas
KR101854110B1 (ko) ＨＥ4ａ의 결정을 위해 사용되는 조성물들 및 방법들
US7745159B2 (en) Methods and compositions for diagnosing carcinomas
US20110104675A1 (en) Methods and Compositions for Diagnosing Carcinomas
HK1214346B (en) Diagnosis of ovarian carcinoma
AU2002333754A1 (en) Diagnosis of carcinomas
HK1158310A (en) Diagnosis of carcinomas
HK1191056B (en) Compositions and methods of use for determination of he4a

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220829